Relationship between MOX genes and antibiotic resistance in Klebsiella pneumoniae strains in nosocomial infections

Document Type : Narrative Review

Authors

1 Lorestan University of Medical Sciences, Khorramabad, Iran

2 Department of Microbiology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Abstract

Drug resistance in microorganisms, specifically bacteria pathogens, is a serious threat to patients worldwide. Multidrug-resistance of bacteria to a broad spectrum of conventional antibiotics is the main hindrance to treating patients admitted to hospital. In this case, the increased emergence of multidrug-resistance mechanisms among Klebsiella pneumoniae nosocomial infections has limited the therapeutic options for treating bacterial infections such as intra-abdominal, urinary tract, and pneumonia infections. The beta-lactamase enzymes in these bacteria, as extended-spectrum beta-lactamases (ESBL), are the primary defense of gram-negative bacteria against a wide range of beta-lactam antibiotics. This review aimed to evaluate the role of MOX genes in the antibiotic resistance of K. pneumoniae strains isolated from hospitalized patients.

Graphical Abstract

Relationship between MOX genes and antibiotic resistance in Klebsiella pneumoniae strains in nosocomial infections

Highlights

  • The mechanism of antibiotic resistance in bacteria should be indicated to choose the best option for treating hospitalized patients.
  • Active drug efflux, inactivating an antibiotic, modifying an antibiotic target, and limiting the uptake of an antibiotic are the primary mechanisms for antibiotic resistance.
  • The resistance of pneumoniae strains to beta-lactams due to the presence of the AmpC beta-lactamase enzyme is one of the most critical challenges in the clinical sector.

Keywords

Main Subjects


Open Access

The journal of MNBA is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

Volume 1, Issue 2
August 2022
Pages 12-17
  • Receive Date: 13 August 2022
  • Revise Date: 25 August 2022
  • Accept Date: 25 August 2022
  • First Publish Date: 25 August 2022